These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 30348241)

  • 1. MULTI-CRITERIA DECISION ANALYSIS AS A DECISION-SUPPORT TOOL FOR DRUG EVALUATION: A PILOT STUDY IN A PHARMACY AND THERAPEUTICS COMMITTEE SETTING.
    Roldán ÚB; Badia X; Marcos-Rodríguez JA; de la Cruz-Merino L; Gómez-González J; Melcón-de Dios A; Caraballo-Camacho MO; Cordero-Ramos J; Alvarado-Fernández MD; Galiana-Auchel JM; Calleja-Hernández MÁ
    Int J Technol Assess Health Care; 2018 Jan; 34(5):519-526. PubMed ID: 30348241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DRUG EVALUATION AND DECISION MAKING IN CATALONIA: DEVELOPMENT AND VALIDATION OF A METHODOLOGICAL FRAMEWORK BASED ON MULTI-CRITERIA DECISION ANALYSIS (MCDA) FOR ORPHAN DRUGS.
    Gilabert-Perramon A; Torrent-Farnell J; Catalan A; Prat A; Fontanet M; Puig-Peiró R; Merino-Montero S; Khoury H; Goetghebeur MM; Badia X
    Int J Technol Assess Health Care; 2017 Jan; 33(1):111-120. PubMed ID: 28434413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implementing reflective multicriteria decision analysis (MCDA) to assess orphan drugs value in the Catalan Health Service (CatSalut).
    Guarga L; Badia X; Obach M; Fontanet M; Prat A; Vallano A; Torrent J; Pontes C
    Orphanet J Rare Dis; 2019 Jun; 14(1):157. PubMed ID: 31248421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient involvement in reflective multicriteria decision analysis to assist decision making in oncology.
    Badia X; Aguarón A; Fernández A; Gimón A; Nafria B; Gaspar B; Guarga L; Gálvez M; Fuentes M; Paco N; Saldaña R
    Int J Technol Assess Health Care; 2019 Jan; 35(1):56-63. PubMed ID: 30730288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multicriteria decision analysis (MCDA) for health technology assessment: the Queensland Health experience.
    Howard S; Scott IA; Ju H; McQueen L; Scuffham PA
    Aust Health Rev; 2019 Oct; 43(5):591-599. PubMed ID: 30205873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact on decision making framework for medicine purchasing in Chinese public hospital decision-making: determining the value of five dipeptidyl peptidase 4 (DPP-4) inhibitors.
    Bao Y; Gao B; Meng M; Ge B; Yang Y; Ding C; Shi B; Tian L
    BMC Health Serv Res; 2021 Aug; 21(1):807. PubMed ID: 34384428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determining the value contribution of selexipag for the treatment of pulmonary arterial hypertension (PAH) in Spain using reflective multi-criteria decision analysis (MCDA).
    Jiménez A; Ais A; Beaudet A; Gil A
    Orphanet J Rare Dis; 2018 Dec; 13(1):220. PubMed ID: 30526673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identifying key unmet needs and value drivers in the treatment of focal-onset seizures (FOS) in patients with drug-resistant epilepsy (DRE) in Spain through Multi-Criteria Decision Analysis (MCDA).
    Villanueva V; Carreño M; Gil-Nagel A; Serrano-Castro PJ; Serratosa JM; Toledo M; Álvarez-Barón E; Gil A; Subías-Labazuy S
    Epilepsy Behav; 2021 Sep; 122():108222. PubMed ID: 34371462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The application of multi-criteria decision analysis in evaluating the value of drug-oriented intervention: a literature review.
    Su P; Zhi K; Xu H; Xiao J; Liu J; Wang Z; Liu Q; Yu Y; Dang H
    Front Pharmacol; 2024; 15():1245825. PubMed ID: 38720775
    [No Abstract]   [Full Text] [Related]  

  • 10. Multi-criteria decision analysis (MCDA): testing a proposed MCDA framework for orphan drugs.
    Schey C; Krabbe PF; Postma MJ; Connolly MP
    Orphanet J Rare Dis; 2017 Jan; 12(1):10. PubMed ID: 28095876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The value of the reflective discussion in decision-making using multi-criteria decision analysis (MCDA): an example of determining the value contribution of tabelecleucel for the treatment of the Epstein Barr virus-positive post-transplant lymphoproliferative disease (EBV
    Badia X; Calleja MÁ; Escudero-Vilaplana V; Pérez-Martínez A; Piñana JL; Poveda JL; Vallès JA
    Orphanet J Rare Dis; 2024 Aug; 19(1):308. PubMed ID: 39180132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bridging health technology assessment (HTA) and efficient health care decision making with multicriteria decision analysis (MCDA): applying the EVIDEM framework to medicines appraisal.
    Goetghebeur MM; Wagner M; Khoury H; Levitt RJ; Erickson LJ; Rindress D
    Med Decis Making; 2012; 32(2):376-88. PubMed ID: 21987539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bridging health technology assessment (HTA) with multicriteria decision analyses (MCDA): field testing of the EVIDEM framework for coverage decisions by a public payer in Canada.
    Tony M; Wagner M; Khoury H; Rindress D; Papastavros T; Oh P; Goetghebeur MM
    BMC Health Serv Res; 2011 Nov; 11():329. PubMed ID: 22129247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a Multicriteria Decision Analysis Framework for Evaluating and Positioning Oncologic Treatments in Clinical Practice.
    Camps C; Badia X; García-Campelo R; García-Foncillas J; López R; Massuti B; Provencio M; Salazar R; Virizuela J; Guillem V
    JCO Oncol Pract; 2020 Mar; 16(3):e298-e305. PubMed ID: 32160482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of multi-criteria decision analysis (MCDA) framework for off-patent pharmaceuticals - an application on improving tender decision making in Indonesia.
    Inotai A; Brixner D; Maniadakis N; Dwiprahasto I; Kristin E; Prabowo A; Yasmina A; Priohutomo S; Németh B; Wijaya K; Kalo Z
    BMC Health Serv Res; 2018 Dec; 18(1):1003. PubMed ID: 30594250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Establishment of a value assessment framework for orphan medicinal products in China.
    Chen H; Xiang Y; Tang X; Hu M
    Orphanet J Rare Dis; 2024 Oct; 19(1):390. PubMed ID: 39428462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Field testing of a multicriteria decision analysis (MCDA) framework for coverage of a screening test for cervical cancer in South Africa.
    Miot J; Wagner M; Khoury H; Rindress D; Goetghebeur MM
    Cost Eff Resour Alloc; 2012 Feb; 10(1):2. PubMed ID: 22376143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing the Preferences for Criteria in Multi-Criteria Decision Analysis in Treatments for Rare Diseases.
    Schey C; Postma MJ; Krabbe PFM; Topachevskyi O; Volovyk A; Connolly M
    Front Public Health; 2020; 8():162. PubMed ID: 32457865
    [No Abstract]   [Full Text] [Related]  

  • 19. Multi-Criteria Decision Analysis (MCDA) Models in Health Technology Assessment of Orphan Drugs-a Systematic Literature Review. Next Steps in Methodology Development?
    Baran-Kooiker A; Czech M; Kooiker C
    Front Public Health; 2018; 6():287. PubMed ID: 30374435
    [No Abstract]   [Full Text] [Related]  

  • 20. A Step Toward the Development of the First National Multi-Criteria Decision Analysis Framework to Support Healthcare Decision Making in Saudi Arabia.
    Al-Jedai A; Almudaiheem H; Alruthia Y; Althemery A; Alabdulkarim H; Ojeil R; Alrumaih A; AlGhannam S; AlMutairi A; Hasnan Z
    Value Health Reg Issues; 2024 May; 41():100-107. PubMed ID: 38306770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.